Edwards Lifesciences (EW) Change in Receivables (2009 - 2026)

Edwards Lifesciences has reported Change in Receivables for 18 years, with the latest figure at $10.2 million in Q2 2026.

• On a quarterly basis, Change in Receivables fell 59.04% year-over-year to $10.2 million in Q2 2026; TTM through Jun 2026 was $82.5 million, a 197.52% increase from a year earlier, with the FY2025 full-year figure at $23.0 million, up 118.98% from the prior year.
• Change in Receivables was $10.2 million for Q2 2026 at Edwards Lifesciences, down from $117.9 million in the prior quarter.
• The five-year high for Change in Receivables was $117.9 million in Q1 2026, with the low at -$105.9 million in Q4 2024.
• Average Change in Receivables over 5 years is $14.2 million, with a median of $14.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables soared 1554.55% in 2023, then sank 3538.46% in 2024.
• Over 5 years, Change in Receivables stood at $1.1 million in 2022, then surged by 1554.55% to $18.2 million in 2023, then plunged by 681.87% to -$105.9 million in 2024, then jumped by 69.41% to -$32.4 million in 2025, then jumped by 131.48% to $10.2 million in 2026.
• The last three Change in Receivables figures came in at $10.2 million (Q2 2026), $117.9 million (Q1 2026), and -$32.4 million (Q4 2025), per Business Quant data.